Comparison · NCT02394730-321bc979
Vorapaxar vs Placebo: Number of Patients in Each Treatment Group With D-dimer <165ng/mL at Week 12
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vorapaxar vs Placebo: Number of Patients in Each Treatment Group With D-dimer <165ng/mL at Week 12. Trial comparisons, record NCT02394730-321bc979. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02394730-321bc979
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0303 | 0.00537 | 0.153 | wilson | |
| Risk in group 2 | 0.0667 | 0.0185 | 0.213 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0364 | -0.185 | 0.0956 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.455 | 0.0434 | 4.76 | log | |
| Odds ratio, group 1 over group 2 | 0.438 | 0.0376 | 5.09 | log | |
| Number needed to treat, for one fewer participant with the outcome on Vorapaxar than on Placebo | 27.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vorapaxar | 2.5mg of vorapaxar po qd~vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks | 1 | 33 | OG000 |
| Group 2 | Placebo | sugar pill po qd~Placebo: Sugar pill taken orally once daily for 12 weeks | 2 | 30 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients in Each Treatment Group With D-dimer <165ng/mL at Week 12
- Description
- Number of patients in each treatment group with d-dimer \<165ng/mL at week 12
- Time frame
- week 12
- Population
Source ClinicalTrials.gov
Trial
- Title
- Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints
- NCT number
- NCT02394730
- Phases
- PHASE1, PHASE2
- Conditions
- HIV
- Interventions
- vorapaxar, Placebo
- Lead sponsor
- Kirby Institute
- Results first posted
- 2019-02-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02394730?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02394730-321bc979